TNF superfamily member immunocytokine and uses thereof

HK40137346APending Publication Date: 2026-09-11GILEAD SCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026124407
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-23
Filing Date
2026-06-05
Publication Date
2026-09-11
Patent Text Reader

Abstract

The present disclosure relates to antibody-cytokine fusion proteins, in particular TNF superfamily member fusion proteins (immunocytokines) and uses thereof. The fusion protein shows antineoplastic activity.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480019527.0 (22) Application Date 2024.03.22 (66) Domestic Priority Data PCT / CN2023 / 083521 2023.03.23 CN (85) PCT International Application Entering National Phase Date 2025.09.16 (86) PCT International Application Application Data PCT / CN2024 / 083357 2024.03.22 (87) PCT International Application Publication Data WO2024 / 193705 EN 2024.09.26 (71) Applicant Gilead Sciences, Inc. Address California, USA (72) Inventors Zhai Qianting, Yang Maiyun, Fei Mingjian, Sun Runzi, Huang Xiaodong (74) Patent Agency Beijing Liu Shen Law Firm 11105 Patent Attorney Qin Jian (51) Int.Cl. C07K 19 / 00 (2006.01) C12N 15 / 62 (2006.01) A61K 47 / 68 (2006.01) A61P 35 / 00 (2006.01) (54) Invention Title: TNF Superfamily Member Immune Cytokines and Their Uses (57) Abstract: This disclosure relates to antibody-cytokine fusion proteins, particularly TNF superfamily member fusion proteins (immune cytokines) and their uses. The fusion proteins exhibit antitumor activity. Claims: 10 pages Description: 44 pages Sequence Listing (Electronic Publication) Drawings: 24 pages CN 121646609 A 2026.03.10 CN 1 21 64 66 09 A

Claims

1. A fusion protein comprising: a first cytokine fragment linked to the C-terminus of a first CH2-CH3 fragment, the first cytokine fragment comprising a first cytokine molecule, or a first cytokine molecule and a third cytokine molecule linked in tandem, and a second cytokine fragment linked to the C-terminus of a second CH2-CH3 fragment, the second cytokine fragment comprising a second cytokine molecule, or a second cytokine molecule and a fourth cytokine molecule linked in tandem, the first CH2-CH3 fragment and the second CH2-CH3 fragment form a dimer, a total of three cytokine molecules linked to the dimer.

2. The fusion protein according to claim 1, wherein the first cytokine fragment comprises the first cytokine molecule and the second cytokine fragment comprises the second cytokine molecule and the fourth cytokine molecule linked in tandem, or the first cytokine fragment comprises the first cytokine molecule and a third cytokine molecule linked in tandem and the second cytokine fragment comprises the second cytokine molecule.

3. The fusion protein according to claim 1 or 2, wherein the first cytokine molecule, the second cytokine molecule, the third cytokine molecule and the fourth cytokine molecule are independently selected from the group consisting of tumor necrosis factor, interleukin, lymphokine, interferon, colony stimulating factor, chemokine and growth factor.

4. The fusion protein according to any one of claims 1 to 3, wherein the first cytokine molecule, the second cytokine molecule, the third cytokine molecule and the fourth cytokine molecule are independently LIGHT, lymphotoxin alpha, lymphotoxin beta or 4-1BBL.

5. The fusion protein according to any one of claims 1 to 4, wherein the first cytokine molecule, the second cytokine molecule, the third cytokine molecule and the fourth cytokine molecule are independently wild-type LIGHT (preferably human LIGHT), truncated LIGHT or muteins thereof; optionally, the wild-type LIGHT, truncated LIGHT or muteins thereof comprise the amino acid sequence of any one of SEQ ID NOs: 25, 26, 58, 59, 68-78, 126-141, 158, 177, 178 and 180; the first cytokine molecule, the second cytokine molecule, the third cytokine molecule and the fourth cytokine molecule are independently wild-type 4-1BBL (preferably human 4-1BBL), truncated 4-1BBL or muteins thereof; optionally, the wild-type 4-1BBL, truncated 4-1BBL or muteins thereof comprise the amino acid sequence of SEQ ID NO: 179; The first, second, third, and fourth cytokine molecules are independently wild-type, truncated lymphotoxin alpha or lymphotoxin beta, or muteins thereof; optionally, the wild-type, truncated lymphotoxin alpha or lymphotoxin beta, or muteins thereof comprise the amino acid sequence of SEQ ID NO: 181, 182.

6. The fusion protein of any one of claims 1-5, wherein the first, second, third, and fourth cytokine molecules are independently truncated LIGHT, optionally the truncated LIGHT comprises the amino acid sequence set forth in SEQ ID NO: 68 or SEQ ID NO:

78.

7. The fusion protein of any one of claims 1-6, wherein the first, second, third, and fourth cytokine molecules are independently LIGHT muteins; optionally, the LIGHT muteins comprise the amino acid sequence set forth in one of SEQ ID NO: 25-26, 58-59, 69-77, 126-141, 158, 177, 178, and 180.

8. The fusion protein of any one of claims 1-7, wherein the dimer is an Fc domain, which is modified to improve correct assembly of the fusion protein.

9. The fusion protein of claim 8, wherein the Fc domain is derived from an IgG, including IgGl, IgG2, IgG3, and IgG4, optionally the Fc domain is derived from a human IgGl or IgG4 Fc domain.

10. The fusion protein according to any one of claims 1 to 9, wherein the first CH2-CH3 fragment and the second CH2-CH3 fragment comprise one or more modifications selected from the group consisting of knobs-into-holes, electrostatic steering of CH3 such as DDKK, DuoBody, SEEDbodies, cFAE, XmAb, Azymetric, and BEAT ® , Optionally, the modifications include a knob-in-hole and / or DDKK.

11. The fusion protein of any one of claims 1-10, wherein the first and second CH2-CH3 fragments form a human IgGl Fc domain with a mutation N297A.

12. The fusion protein of any one of claims 1-11, wherein the first or second CH2-CH3 fragment further comprises one or more mutations selected from the group consisting of Y349C, T366S, L368A, and Y407V; and the other comprises mutations S354C and / or T366W.

13. The fusion protein of any one of claims 1-12, wherein the first cytokine fragment is connected to the C-terminal end of the first CH2-CH3 fragment, directly or via a linker; and / or the second cytokine fragment is connected to the C-terminal end of the second CH2-CH3 fragment, directly or via a linker.

14. The fusion protein of any one of claims 1 to 13, wherein the C-terminus of a CH3 domain in the first CH2-CH3 fragment is fused directly or via a first linker A to the N- terminus of the first cytokine fragment; and / or the C-terminus of a CH3 domain in the second CH2-CH3 fragment is fused directly or via a first linker B to the N-terminus of the second cytokine fragment.

15. The fusion protein of any one of claims 1 to 14, wherein the first cytokine molecule is fused directly or via a second linker A to the third cytokine molecule; and / or the second cytokine molecule is fused directly or via a second linker B to the fourth cytokine molecule.

16. The fusion protein of any one of claims 1 to 15, wherein the C-terminus of the first cytokine molecule is fused directly or via a second linker A to the N-terminus of the third cytokine molecule; and / or the C-terminus of the second cytokine is fused directly or via a second linker B to the N-terminus of the fourth cytokine. Optionally, the first linker A and the first linker B are independently absent or selected from the group consisting of SEQ ID NOs: 81, 82, 83, 84, and 89, G, and (GGGGS)n, wherein n = 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

17. The fusion protein according to any one of claims 1 to 16, wherein the first linker A, the first linker B, the second linker A and the second linker B are independently absent or selected from the group consisting of VH-CH1 linker (SEQ ID NO: 82), VL-CL linker (SEQ ID NO: 83), CH2-CH3 linker (SEQ ID NO: 81), IgM tail linker (SEQ ID NO: 84), GGGGSGGGGSGGGGSGGGGT (SEQ ID NO: 89), G, and (GGGGS)n, wherein n = 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 18. The fusion protein of any one of claims 1 to 17, wherein the first linker A and the first linker B are independently absent or comprise an amino acid sequence as set forth in any one of SEQ ID NOs: 81-90.

19. The fusion protein of any one of claims 1 to 18, wherein the first linker A and the first linker B are the same or different.

20. The fusion protein of any one of claims 1 to 19, wherein the second linker A and the second linker B are independently absent or are G, GGGGSGGGGSGGGGSGGGGT, or (GGGGS)n, wherein n = 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

21. The fusion protein of any one of claims 1 to 20, wherein the second linker A and the second linker B are independently of each other absent or comprise the amino acid G or an amino acid sequence as set forth in any one of SEQ ID NOs: 85-89.

22. The fusion protein of any one of claims 1 to 21, comprising a first antigen binding fragment and a second antigen binding fragment, which are linked to the N-terminus of the first CH2-CH3 fragment and the second CH2-CH3 fragment, respectively. ​ 23. The fusion protein of claim 22, wherein the first and second antigen binding fragments are independently selected from the group consisting of a diabody, a Fab, a Fab', a F(ab')2, a Fv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv)2, a bispecific dsFv (dsFv-dsFv'), a disulfide stabilized diabody (ds diabody), a single chain Fv (scFv), a scFv dimer (bivalent diabody), a multi-specific antibody formed from a portion of an antibody comprising one or more CDRs, a camelid-derived single domain antibody, a nanobody, a domain antibody, a bivalent domain antibody, or any other antibody fragment.

24. The fusion protein of claim 22 or 23, wherein the first antigen binding fragment is a scFv or a Fab that specifically binds to a first antigen; and the second antigen binding fragment is a Fab that specifically binds to a second antigen.

25. The fusion protein of any one of claims 22-24, comprising a first heavy chain comprising, from the N-terminus to the C-terminus, the operably linked first antigen binding fragment, the first CH2-CH3 fragment, and the first cytokine fragment; a second heavy chain comprising, from the N-terminus to the C-terminus, the operably linked second antigen binding fragment, the second CH2-CH3 fragment, and the second cytokine fragment.

26. The fusion protein of any one of claims 22-25, further comprising a first light chain paired with the first antigen binding fragment to form a heterodimer; and / or a second light chain paired with the second antigen binding fragment to form a heterodimer.

27. The fusion protein of any one of claims 22-26, wherein the first antigen and the second antigen are each independently selected from the group consisting of FAP, HER2, PDL-1, PD-1, EGFR, VEGFR, VEGF, CCR8, OX-40, 41BB, Angiopoietin-2, IL-4Ra, BCMA, Blys, BTNO2, C5, CD122, CD13, CD133, CD137, CD138, CD16a, CD19, CD20, CD22, CD27, CD28, CD3, CD30, CD33, CD38, CD40, CD47, CD-8, CEA, CGPR / CGRPR, CSPGs, CTLA4, CTLA-4, DLL-4, EpCAM, Factor IXa, Factor X, GITR, GP130, Her3, HSG, ICOS, IGF1, IGF1 / 2, IGF-1R, IGF2, IGFR, IL-1, IL-12, IL-12p40, IL-13, IL-17A, IL-1b, IL-23, IL-5, IL-6, IL-6R, Lag-3, LAG3, MAG, Met, NgR, NogoA, OMGp, OX40, PDGFR, PSMA, RGMA, RGMB, SARS-CoV-2, Te38, TIM-3, TNF, TNFa, TROP-2, and TWEAK.

28. The fusion protein of any one of claims 22-27, wherein the first antigen and the second antigen are each independently selected from the group consisting of FAP, HER2, PDL-1, and EGFR.

29. The fusion protein of any one of claims 22-28, wherein the first antigen and the second antigen are both FAP, HER2, EGFR, or PDL-1, or the first antigen is HER2 and the second antigen is FAP.

30. The fusion protein of any one of claims 1-29, wherein the fusion protein is monovalent or bivalent, monospecific or bispecific.

31. The fusion protein of any one of claims 1-30, wherein the first cytokine molecule, the second cytokine molecule, and the third cytokine molecule have the same amino acid sequence; or the first cytokine molecule, the second cytokine molecule, and the fourth cytokine molecule have the same amino acid sequence.

32. The fusion protein of any one of claims 26-31, wherein the first light chain and the second light chain independently comprise the amino acid sequence set forth as SEQ ID NO: 1, 29, 91, or 94. ​ 33. The fusion protein of any one of claims 22-32, wherein the first heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 23, 28, 31, 32, 35, 37, 39, 41, 43, 45, 47, 49, 51, 52, 53, 55, 57, 61, 63, 65, 67, 93, 96, 98, 99, 100, 102, 104, 107, 109, 111, 113, 114, 117, 119, 121, 123, 125, 143, 145, 147, 149, 151, 153, 157, 155, 160, 162, 164, 166, 167, 169, 171, 173, or 175.

34. The fusion protein of any one of claims 22-33, wherein the second heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 2, 5, 7, 9, 11, 13, 15, 17, 19, 21, 24, 27, 30, 33, 34, 36, 38, 40, 42, 44, 46, 48, 50, 54, 56, 60, 62, 64, 66, 92, 95, 97, 101, 103, 105, 106, 108, 110, 112, 115, 116, 118, 120, 122, 124, 142, 144, 146, 148, 150, 152, 154, 156, 159, 161, 163, 165, 168, 170, 172, 174, or 176.

35. The fusion protein of any one of claims 22-34, wherein the fusion protein is selected from the following: (1) both the first and second light chains comprise an amino acid sequence as set forth in SEQ ID NO: 1, the first heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 3, and the second heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 2; (2) both the first and second light chains comprise an amino acid sequence as set forth in SEQ ID NO: 1, the first heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 4, and the second heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 2; (3) both the first and second light chains comprise an amino acid sequence as set forth in SEQ ID NO: 1, the first heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 6, and the second heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 5; (4) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 8, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 7; (5) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 10, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 9; (6) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 11, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 11; (7) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 14, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 13; (8) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 16, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15; (9) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 18, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 17; (10) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 20, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 19; (11) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 22, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 21; (12) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 23, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 24; (13) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 27, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 28; (14) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 29, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 30, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 31; (15) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 32, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 33; (16) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 34, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 35; (17) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 37, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 36; (18) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 39, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 38; (19) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 41, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 40; (20) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 29, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 42, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 43; or (21) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 45, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 44; (22) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 47, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 46; (23) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 49, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 48; (24) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 51, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 50; (25) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 52, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 2; (26) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 53, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 2; (27) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 55, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 54; (28) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 57, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 56; (29) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 61, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 60; (30) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 63, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 62; (31) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 65, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 64; (32) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 67, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 66; (33) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 91, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 92, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 93; (34) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 94, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 95, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 96; (35) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 98, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 97; (36) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 99, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 97; (37) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 100, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 101; (38) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 102, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 103; (39) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 104, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 105; (40) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 107, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 106; (41) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 109, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 108; (42) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 111, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 110; (43) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 113, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 112; (44) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 114, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 115; (45) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 117, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 116; (46) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 119, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 118; (47) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 121, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 120; (48) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 123, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 122; (49) the second light chain comprises an amino acid sequence as set forth in SEQ ID NO: 1, the first heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 124, and the second heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 4; (50) the second light chain comprises an amino acid sequence as set forth in SEQ ID NO: 1, the first heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 2, and the second heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 125; (51) the first and second light chains both comprise an amino acid sequence as set forth in SEQ ID NO: 1, the first heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 143, and the second heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 142; (52) the first and second light chains both comprise an amino acid sequence as set forth in SEQ ID NO: 1, the first heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 145, and the second heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 144; (53) the first and second light chains both comprise an amino acid sequence as set forth in SEQ ID NO: 1, the first heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 147, and the second heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 146; (54) the first and second light chains both comprise an amino acid sequence as set forth in SEQ ID NO: 1, the first heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 149, and the second heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 148; (55) the first and second light chains both comprise an amino acid sequence as set forth in SEQ ID NO: 1, the first heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 151, and the second heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 150; (56) the first and second light chains both comprise an amino acid sequence as set forth in SEQ ID NO: 1, the first heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 153, and the second heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 152; (57) the first and second light chains both comprise an amino acid sequence as set forth in SEQ ID NO: 1, the first heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 155, and the second heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 154; (58) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 157, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 156; (59) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 160, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 159; (60) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 162, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 161; (61) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 164, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 163; (62) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 166, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 165; (63) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 168, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 167; (64) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 170, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 169; (65) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 172, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 171; (66) the first and second light chains both comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 174, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 173; (67) both the first and second light chains comprise the amino acid sequence set forth in SEQ ID NO: 1, the first heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 176, and the second heavy chain comprises the amino acid sequence set forth in SEQ ID NO:

175.

36. An isolated polynucleotide encoding the first heavy chain, the first light chain, the second heavy chain, or the second light chain of the fusion protein of any one of claims 1 to 35.

37. A set of isolated polynucleotides comprising polynucleotides encoding the first heavy chain, the first light chain, the second heavy chain, and the second light chain of the fusion protein of any one of claims 1 to 35.

38. An isolated vector comprising the isolated polynucleotide of claim 36 or 37.

39. A host cell comprising the isolated polynucleotide of claim 36, the set of isolated polynucleotides of claim 37, or the isolated vector of claim 38.

40. A pharmaceutical composition comprising the fusion protein of any one of claims 1 to 35, the isolated polynucleotide of claim 36, the set of isolated polynucleotides of claim 37, the isolated vector of claim 38, or the host cell of claim 39, and a pharmaceutically acceptable carrier.

41. A kit comprising the fusion protein of any one of claims 1 to 35, the isolated polynucleotide of claim 36, the set of isolated polynucleotides of claim 37, the isolated vector of claim 38, the host cell of claim 39, or the pharmaceutical composition of claim 40.

42. Use of the fusion protein of any one of claims 1 to 35, the isolated polynucleotide of claim 36, the set of isolated polynucleotides of claim 37, the isolated vector of claim 38, the host cell of claim 39, the pharmaceutical composition of claim 40, or the kit of claim 41 in the manufacture of a medicament for the prevention or treatment of a disease, or in the manufacture of a kit for the diagnosis of a disease.

43. The use of claim 42, wherein the disease comprises a tumor, optionally a solid tumor.

44. A method of diagnosing, preventing, or treating a disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the fusion protein of any one of claims 1 to 36, the isolated polynucleotide of claim 36, the set of isolated polynucleotides of claim 37, the isolated vector of claim 38, the host cell of claim 39, the pharmaceutical composition of claim 40, or the kit of claim 41.

45. The method of claim 44, wherein the disease comprises a tumor, optionally a solid tumor.

46. A method for producing the fusion protein of any one of claims 1 to 35, the method comprising introducing a first expression vector encoding the first heavy chain, a second expression vector encoding the first light chain, a third expression vector encoding the second heavy chain, and / or a fourth expression vector encoding the second light chain into one host cell, or into separate host cells, and expressing the first expression vector, the second expression vector, the third expression vector, and the fourth expression vector under appropriate conditions.

47. The method of claim 46, wherein the host cell is a eukaryotic cell.

48. The method of claim 46 or 47, wherein, The host cell is a mammalian cell.